特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
365165

脳卒中:疫学・患者に基づいた市場予測、治療アルゴリズム、および上市薬・パイプライン薬の分析

Ischemic Stroke Market and Forecast Analysis 2024

出版日: | 発行: Datamonitor Healthcare | ページ情報: 英文 163 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.15円
脳卒中:疫学・患者に基づいた市場予測、治療アルゴリズム、および上市薬・パイプライン薬の分析
出版日: 2019年01月07日
発行: Datamonitor Healthcare
ページ情報: 英文 163 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、虚血性脳梗塞の治療薬について取り上げ、イグザレルトの解毒剤としてのアンデキサネットアルファの承認が薬剤の売上に及ぼす影響、虚血性脳梗塞治療薬の売上に最も大きな影響を及ぼす患者サブグループ、医師の処方動向に影響を及ぼす最も重要な要因、虚血性脳梗塞の治療で最大の市場シェアを構成する先発薬、虚血性脳梗塞の急性治療・二次予防の双方に最も一般的に処方される治療薬などについて、分析しています。

予測:虚血性脳梗塞

  • エグゼクティブサマリー
  • 市場概要・動向
  • 市場定義・調査手法
  • Brilinta (ticagrelor)
  • Plavix (clopidogrel)
  • Xarelto (rivaroxaban)
  • 1次調査手法

治療:虚血性脳梗塞

  • エグゼクティブサマリー
  • 1次調査手法
  • 疾患の定義・診断
  • 現在の治療オプション
  • 処方動向

疫学:脳卒中

  • エグゼクティブサマリー
  • 疾患の背景
  • ソース・手法
  • 予測
  • 疫学者の考察
  • 能力と限界

上市薬:虚血性脳梗塞

  • エグゼクティブサマリー
  • 製品概要
  • 製品プロファイル:Activase
  • 製品プロファイル:Aggrenox
  • 製品プロファイル:Plavix

パイプライン:虚血性脳梗塞

  • エグゼクティブサマリー
  • 臨床パイプラインの概要
  • 最近中止された薬剤
  • 製品プロファイル (後期段階) :Ampyra
  • 製品プロファイル (後期段階) :Brilinta
  • 製品プロファイル (後期段階) :Xarelto
目次
Product Code: DMKC12560

Overview

Stroke is the second most common cause of death and a major cause of disability worldwide. A stroke occurs when there is a blockage or bleed in the cerebrovascular system that leads to either a neurological deficit persisting beyond 24 hours or death. The majority of strokes occur due to blockages, and these are known as ischemic strokes. Strokes caused by bleeding are known as hemorrhagic strokes.

Market Snapshot

  • Market growth will slow as Plavix continues to lose market share as generic clopidogrel uptake increases.
  • Alteplase is prescribed to 65% of ischemic stroke patients in the US, Japan, and five major EU markets who receive thrombolytic therapy as an acute treatment.
  • Overall disease burden is expected to greatly increase, with ischemic stroke more common than hemorrhagic stroke.
  • Activase will continue to experience strong uptake while Aggrenox and Plavix face declining sales.
  • The large-scale Xarelto study was recently suspended, and there are no other pipeline drugs in Phase III trials.

TABLE OF CONTENTS

FORECAST: ISCHEMIC STROKE (Published on 02 July 2018)

  • OVERVIEW
  • MARKET OVERVIEW AND TRENDS
  • MARKET DEFINITION AND METHODOLOGY
  • PRIMARY RESEARCH METHODOLOGY
  • BIBLIOGRAPHY
  • PRODUCT PROFILE: ASPIRIN
  • PRODUCT PROFILE: PLAVIX

TREATMENT: ISCHEMIC STROKE (Published on 14 December 2016)

  • OVERVIEW
  • EXECUTIVE SUMMARY
  • PRIMARY RESEARCH METHODOLOGY
  • DISEASE DEFINITION AND DIAGNOSIS
  • CURRENT TREATMENT OPTIONS
  • PRESCRIBING TRENDS

EPIDEMIOLOGY: STROKE (Published on 07 January 2019)

  • OVERVIEW
  • DISEASE BACKGROUND
  • METHODOLOGY
  • FORECAST
  • BIBLIOGRAPHY
  • APPENDIX: ADDITIONAL SOURCES

MARKETED DRUGS: ISCHEMIC STROKE (Published on 02 July 2018)

  • OVERVIEW
  • EXECUTIVE SUMMARY
  • PRODUCT OVERVIEW
  • PRODUCT PROFILE: ACTIVASE
  • PRODUCT PROFILE: AGGRENOX
  • PRODUCT PROFILE: ASPIRIN
  • PRODUCT PROFILE: PLAVIX

PIPELINE: ISCHEMIC STROKE (Published on 02 July 2018)

  • OVERVIEW
  • EXECUTIVE SUMMARY
  • CLINICAL PIPELINE OVERVIEW
  • RECENTLY DISCONTINUED DRUGS
  • ADDITIONAL PHARMA INTELLIGENCE PIPELINE RESOURCES

LIST OF FIGURES

  • Figure 1: Ischemic stroke market forecast across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 2: Ischemic stroke market forecast across the US, Japan, and five major EU markets, by drug, 2016-25
  • Figure 3: Patient-based forecast methodology for ischemic stroke
  • Figure 4: Price sources and calculations, by country
  • Figure 5: Datamonitor Healthcare's drug assessment summary of Aspirin for ischemic stroke
  • Figure 6: Datamonitor Healthcare's drug assessment summary of Aspirin for ischemic stroke
  • Figure 7: Aspirin sales for ischemic stroke across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 8: Plavix for ischemic stroke - SWOT analysis
  • Figure 9: Datamonitor Healthcare's drug assessment summary of Plavix for ischemic stroke
  • Figure 10: Datamonitor Healthcare's drug assessment summary of Plavix for ischemic stroke
  • Figure 11: Plavix sales for ischemic stroke across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 12: Mean percentage of patients presenting with stroke-like symptoms diagnosed with particular indications, by country, 2015
  • Figure 13: Mean percentage of ischemic stroke patients receiving each treatment regimen in the US, Japan, and five major EU markets, by country, 2015
  • Figure 14: Mean percentage of ischemic stroke patients receiving each thrombolytic therapy in the US, Japan, and five majorEU markets, by country, 2015
  • Figure 15: Mean percentage of ischemic stroke patients receiving each neuroprotective therapy in the US, Japan, and five major EU markets, by country, 2015
  • Figure 16: Ischemic stroke patients receiving the top five antiplatelet/anticoagulant medications in the acute treatment setting, by country, 2015
  • Figure 17: Ischemic stroke patients receiving the top five antiplatelet/anticoagulant medications in the secondary prevention setting at first-line, by country, 2015
  • Figure 18: Mean percentage of ischemic stroke patients who progress to second-line treatment in the secondary prevention setting, by country, 2015
  • Figure 19: Ischemic stroke patients receiving the top five antiplatelet/anticoagulant medications in secondary prevention setting at second-line, by country, 2015
  • Figure 20: Trends in diagnosed incident cases of ischemic stroke in the US, Japan, and five major EU markets, by country, 2018-38
  • Figure 21: Trends in diagnosed incident cases of hemorrhagic stroke in the US, Japan, and five major EU markets, by country, 2018-38
  • Figure 22: Trend in diagnosed prevalent cases of ischemic stroke in the US, Japan, and five major EU markets, by country, 2018-38
  • Figure 23: Trends in diagnosed prevalent cases of hemorrhagic stroke in the US, Japan, and five major EU markets, by country, 2018-38
  • Figure 24: Activase for ischemic stroke - SWOT analysis
  • Figure 25: Datamonitor Healthcare's drug assessment summary of Activase for ischemic stroke
  • Figure 26: Datamonitor Healthcare's drug assessment summary of Activase for ischemic stroke
  • Figure 27: Aggrenox for ischemic stroke - SWOT analysis
  • Figure 28: Datamonitor Healthcare's drug assessment summary of Aggrenox for ischemic stroke
  • Figure 29: Datamonitor Healthcare's drug assessment summary of Aggrenox for ischemic stroke
  • Figure 30: Datamonitor Healthcare's drug assessment summary of Aspirin for ischemic stroke
  • Figure 31: Datamonitor Healthcare's drug assessment summary of Aspirin for ischemic stroke
  • Figure 32: Aspirin sales for ischemic stroke across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 33: Plavix for ischemic stroke - SWOT analysis
  • Figure 34: Datamonitor Healthcare's drug assessment summary of Plavix for ischemic stroke
  • Figure 35: Datamonitor Healthcare's drug assessment summary of Plavix for ischemic stroke
  • Figure 36: Plavix sales for ischemic stroke across the US, Japan, and five major EU markets, by country, 2016-25

LIST OF TABLES

  • Table 1: Distribution of total market sales across ischemic stroke subgroups, 2016-25
  • Table 2: Summary of drug classes and molecules included in Datamonitor Healthcare's ischemic stroke patient-based forecast
  • Table 3: Patent expiries occurring within the ischemic stroke market during the forecast period, 2016-25
  • Table 4: Exchange rates used for calculating prices
  • Table 5: Cardiologists and neurologists surveyed for the ischemic stroke primary research study, 2015
  • Table 6: Aspirin franchise sales for ischemic stroke across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 7: Plavix drug profile
  • Table 8: Plavix pivotal trial data in ischemic stroke
  • Table 9: Plavix ongoing late-phase clinical trials in ischemic stroke
  • Table 10: Plavix sales for ischemic stroke across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 11: Cardiologists and neurologists surveyed for the ischemic stroke primary research study, 2015
  • Table 12: Overview of risk factors for a first transient ischemic attack or ischemic stroke
  • Table 13: Mean percentage of ischemic stroke patients that have co-morbidities in the US, Japan, and five major EU markets, by country, 2015
  • Table 14: Common transient ischemic attack and ischemic stroke symptoms
  • Table 15: Overview of tests used in ischemic stroke and transient ischemic attack patients, by major category
  • Table 16: Treatments available for ischemic stroke across the US, Japan, and five major EU markets
  • Table 17: Mean percentage of ischemic stroke patients receiving each type of therapy in the US, Japan, and five major EU markets, by country, 2015
  • Table 18: Overview of inclusion and exclusion criteria for patients eligible for alteplase treatment in the US
  • Table 19: Mean percentage of ischemic stroke patients that progress to secondary prevention in the US, Japan, and five major EU markets, by country, 2015
  • Table 20: Sources used for the epidemiological analysis of stroke incidence in the US, Japan, and five major EU markets, by country
  • Table 21: Sources used for the epidemiological analysis of stroke prevalence in the US, Japan, and five major EU markets, by country
  • Table 22: Diagnosed incident cases of ischemic stroke in the US, Japan, and five major EU markets, by country, 2018-38
  • Table 23: Diagnosed incident cases of hemorrhagic stroke in the US, Japan, and five major EU markets, by country, 2018-38
  • Table 24: Diagnosed prevalent cases of ischemic stroke in the US, Japan, and five major EU markets, by country, 2018-38
  • Table 25: Diagnosed prevalent cases of hemorrhagic stroke in the US, Japan, and five major EU markets, by country, 2018-38
  • Table 26: Key marketed drugs for ischemic stroke
  • Table 27: Activase drug profile
  • Table 28: Activase pivotal trial data in ischemic stroke
  • Table 29: Aggrenox drug profile
  • Table 30: Aggrenox pivotal trial data in ischemic stroke
  • Table 31: Aggrenox late-phase trial data in ischemic stroke
  • Table 32: Aspirin franchise sales for ischemic stroke across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 33: Plavix drug profile
  • Table 34: Plavix pivotal trial data in ischemic stroke
  • Table 35: Plavix ongoing late-phase clinical trials in ischemic stroke
  • Table 36: Plavix sales for ischemic stroke across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 37: Late-stage compounds that were recently discontinued for ischemic stroke
  • Table 38: Ampyra drug profile
  • Table 39: Ampyra late-phase trial data in ischemic stroke
  • Table 40: Brilinta drug profile
  • Table 41: Brilinta late-phase trial data in ischemic stroke
  • Table 42: Desmoteplase drug profile
  • Table 43: Desmoteplase late-phase trial data in ischemic stroke
  • Table 44: Xarelto drug profile
  • Table 45: Xarelto late-phase trial data in ischemic stroke
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.